Skip to content

Cognitive Bias Modification for Paranoia

Cognitive Bias Modification for Paranoia: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN90749868
Enrollment
60
Registered
2016-05-12
Start date
2016-04-14
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Mental Health, Primary sub-specialty: Personality disorder - paranoia Mental and Behavioural Disorders

Interventions

There will be two sets of material and the participants will be randomly assigned to one or the other group. CBM-pa consists of 40 scenarios in each session (six weekly sessions), for a total of 240 d
for each CBM-pa scenario, participants will have to read three lines on a computer screen, completing missing words and answer questions about each scenario in a way that encourages more helpful belie

Sponsors

Guy's Campus, King's College London
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Any diagnosis featuring clinically significant persecutory or paranoid symptoms, present for at least the preceding month 2. Above threshold (>2 on item 6) on the paranoia item of the Positive and Negative Symptoms Scale 3. Displaying a baseline interpretation bias, as measured by the 'Scrambled Sentences Task' 4. Stable on medication for at least the last 3 mths and expected to be so for study duration 5. Age 18-65 6. Capacity to consent

Exclusion criteria

Exclusion criteria: 1. Severe cognitive impairment 2. Illiteracy 3. Major physical illness (cancer, heart disease, stroke) 4. Major substance or alcohol misuse 5. Currently receiving, or soon due to receive, a psychological intervention targeting the same psychological mechanisms as CBM-pa (paranoid beliefs), or having done so in the last 3 months

Design outcomes

Primary

MeasureTime frame
1. Paranoid beliefs, measured using the Ambiguous passages task at baseline T0, six weekly sessions (Ti), end of treatment (T1), one month (T2) and three months follow-ups (T3) 2. Paranoid symptoms, measured using the Positive and Negative Symptoms Scale (item 6 only) at baseline T0, six weekly sessions (Ti), end of treatment (T1), one month (T2) and three months follow-up (T3) 3. Vulnerability to stress measured using the visual analogue score (VAS) at end of treatment (T1), pre and post a virtual reality assessment (VR)

Secondary

MeasureTime frame
1. Paranoid beliefs, measured using the Scrambled sentences task and the Cognitive Flexibility Scale at baseline T0 and end of treatment (T1). 2. Paranoid symptoms, measured using the Paranoia Scale, Paranoid Thoughts Scale, Peter’s Delusions Inventory, at baseline T0 and end of treatment (T1). 3. Vulnerability to stress measured using the laughter task at end of treatment (T1).

Countries

England, United Kingdom

Contacts

Public ContactJenny Yiend

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026